CanSino Biologics Inc
SSE:688185

Watchlist Manager
CanSino Biologics Inc Logo
CanSino Biologics Inc
SSE:688185
Watchlist
Price: 62.11 CNY -8.12% Market Closed
Market Cap: 7.1B CNY
Have any thoughts about
CanSino Biologics Inc?
Write Note

CanSino Biologics Inc
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CanSino Biologics Inc
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
CanSino Biologics Inc
SSE:688185
Other Current Liabilities
ÂĄ792.1m
CAGR 3-Years
51%
CAGR 5-Years
62%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Current Liabilities
ÂĄ530.5m
CAGR 3-Years
-8%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Current Liabilities
ÂĄ299.9m
CAGR 3-Years
-2%
CAGR 5-Years
-10%
CAGR 10-Years
11%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Current Liabilities
ÂĄ3B
CAGR 3-Years
13%
CAGR 5-Years
20%
CAGR 10-Years
22%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Current Liabilities
ÂĄ3.6B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
13%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Current Liabilities
ÂĄ101.9m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CanSino Biologics Inc
Glance View

Market Cap
7.1B CNY
Industry
Pharmaceuticals

CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,946 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Intrinsic Value
67.83 CNY
Undervaluation 8%
Intrinsic Value
Price

See Also

What is CanSino Biologics Inc's Other Current Liabilities?
Other Current Liabilities
792.1m CNY

Based on the financial report for Dec 31, 2023, CanSino Biologics Inc's Other Current Liabilities amounts to 792.1m CNY.

What is CanSino Biologics Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
62%

Over the last year, the Other Current Liabilities growth was -6%. The average annual Other Current Liabilities growth rates for CanSino Biologics Inc have been 51% over the past three years , 62% over the past five years .

Back to Top